Longitudinal heterogeneity in glioblastoma: moving targets in recurrent versus primary tumors
Abstract Background Molecularly targeted therapies using receptor inhibitors, small molecules or monoclonal antibodies are routinely applied in oncology. Verification of target expression should be mandatory prior to initiation of therapy, yet, determining the expression status is most challenging i...
Збережено в:
| Автори: | , , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
BMC
2019-03-01
|
| Серія: | Journal of Translational Medicine |
| Предмети: | |
| Онлайн доступ: | http://link.springer.com/article/10.1186/s12967-019-1846-y |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|